» Articles » PMID: 16179569

A New Visual Rating Scale to Assess Strategic White Matter Hyperintensities Within Cholinergic Pathways in Dementia

Overview
Journal Stroke
Date 2005 Sep 24
PMID 16179569
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: One possible mechanism of cognitive decline in individuals with subcortical vascular disease is disruption of cholinergic fibers by ischemic lesions, such as strategically located white matter hyperintensities (WMH). The authors applied a new MRI visual rating scale to assess WMH within cholinergic pathways in patients with Alzheimer Disease (AD) and subcortical ischemic microvascular disease.

Methods: Subjects included 60 AD patients with and without WMH, matched for age, as well as 15 control subjects. A visual rating scale was developed based on published immunohistochemical tracings of the cholinergic pathways in humans. On 4 selected axial images, the severity of WMH in the cholinergic pathways was rated on a 3-point scale for ten regions, identified with major anatomical landmarks. A published, consensus-derived, general WMH scale was also applied. All subjects underwent standardized neuropsychological testing.

Results: The Cholinergic Pathways HyperIntensities Scale showed reliability and was validated with volumetry of strategic WMH. After accounting for age and education in a multiple linear regression model, The Cholinergic Pathways HyperIntensities Scale ratings were associated with impaired performance on the Mattis Dementia Rating Scale (r=0.40; P=0.02) and accounted for 12% of the variance (corrected r2). A similar model was not significant for general WMH scores.

Conclusions: The new MRI rating scale for WMH in cholinergic pathways is reliable and shows stronger correlations with cognitive performance than a general WMH rating scale in AD with WMH. This new rating scale provides indirect evidence that localization of WMH within neurotransmitter systems may contribute to cognitive decline.

Citing Articles

Selecting a Brief Cognitive Screening Test Based on Patient Profile: It Is Never Too Early to Start.

Garcia-Lluch G, Muedra-Moreno A, Garcia-Zamora M, Gomez B, Sanchez-Roy R, Moreno L J Clin Med. 2024; 13(19).

PMID: 39408069 PMC: 11477581. DOI: 10.3390/jcm13196009.


Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders.

Kim Y, Lim J, Suh C, Heo H, Roh J, Cheong E Alzheimers Res Ther. 2024; 16(1):185.

PMID: 39148136 PMC: 11325579. DOI: 10.1186/s13195-024-01536-2.


Intelligent cholinergic white matter pathways algorithm based on U-net reflects cognitive impairment in patients with silent cerebrovascular disease.

Fei B, Cheng Y, Liu Y, Zhang G, Ge A, Luo J Stroke Vasc Neurol. 2024; 9(6):699-707.

PMID: 38569895 PMC: 11791635. DOI: 10.1136/svn-2023-002976.


White matter hyperintensities in cholinergic pathways correlates of cognitive impairment in moyamoya disease.

Xu D, Yu X, Hu J, Yu Y, Wang L, Jiang B Eur Radiol. 2023; 34(7):4596-4606.

PMID: 38092950 DOI: 10.1007/s00330-023-10489-3.


Dynamic alterations in the amplitude of low-frequency fluctuation in patients with cerebral small vessel disease.

Song J, Lei T, Li Y, Zhou L, Yan W, Li H Front Mol Neurosci. 2023; 16:1200756.

PMID: 37808469 PMC: 10556663. DOI: 10.3389/fnmol.2023.1200756.